Ellie Davison
@drelliedavison.bsky.social
#ProstateCancer Research @prostateukprofs.bsky.social
🧬💊🔬🧪👩🏽🔬💡🫶
🧬💊🔬🧪👩🏽🔬💡🫶
If you're looking for support with your personal development and building the skills needed for career progression, take a look at our #prostatecancer Researcher Mentoring Scheme.
You can register as a mentor, a mentee, or both!
prostatecanceruk.org/research/for...
You can register as a mentor, a mentee, or both!
prostatecanceruk.org/research/for...
February 3, 2025 at 6:42 PM
If you're looking for support with your personal development and building the skills needed for career progression, take a look at our #prostatecancer Researcher Mentoring Scheme.
You can register as a mentor, a mentee, or both!
prostatecanceruk.org/research/for...
You can register as a mentor, a mentee, or both!
prostatecanceruk.org/research/for...
How do you write an effective response to reviewers when resubmitting after peer review?
Discover the dos and don'ts with this expert advice direct from the editors at European Urology @euplatinum.bsky.social @vickersbiostats.bsky.social.
Grab a ☕and read more: doi.org/10.1016/j.eu...
Discover the dos and don'ts with this expert advice direct from the editors at European Urology @euplatinum.bsky.social @vickersbiostats.bsky.social.
Grab a ☕and read more: doi.org/10.1016/j.eu...
January 29, 2025 at 9:57 AM
How do you write an effective response to reviewers when resubmitting after peer review?
Discover the dos and don'ts with this expert advice direct from the editors at European Urology @euplatinum.bsky.social @vickersbiostats.bsky.social.
Grab a ☕and read more: doi.org/10.1016/j.eu...
Discover the dos and don'ts with this expert advice direct from the editors at European Urology @euplatinum.bsky.social @vickersbiostats.bsky.social.
Grab a ☕and read more: doi.org/10.1016/j.eu...
We're looking for mentors who are senior in their field, as well as mentors who've recently established independence, so that our mentees receive the right support at the right time in our #prostatecancer Researcher Mentoring Scheme.
Find out more and register: prostatecanceruk.org/research/for...
Find out more and register: prostatecanceruk.org/research/for...
January 27, 2025 at 10:21 AM
We're looking for mentors who are senior in their field, as well as mentors who've recently established independence, so that our mentees receive the right support at the right time in our #prostatecancer Researcher Mentoring Scheme.
Find out more and register: prostatecanceruk.org/research/for...
Find out more and register: prostatecanceruk.org/research/for...
[2/3]
Programme details 👇
Programme details 👇
![16:00 CET [15:00 GMT] Welcome and introduction.
16:05 CET [15:05 GMT] Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Jared Burks - M.D. Anderson Cancer Center, Houston.
16:45 CET [15:35 GMT] Mapping prostate cancer: Insights from spatial transcriptomics and 3D imaging. Early Career Research Talk - Sandy Figiel - University of Oxford.
17:05 CET [16:05 GMT] Title to be confirmed. Alfonso Urbanucci and Matti Nykter - Tampere University, Tampere.
17:50 CET [16:50 GMT] General Discussions and Closing remarks.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:xl4r4hli35b3hzmccf2ho2t7/bafkreidobs5cr2numytlvgge2ff4ft6xllzb5xa2ljk25js4pxnojzdd5a@jpeg)
January 23, 2025 at 10:34 AM
[2/3]
Programme details 👇
Programme details 👇
Professor Helen McCarthy and her team @qubelfastofficial.bsky.social are developing an mRNA vaccine to treat #prostatecancer that has spread or come back.
Since 2013 we have supported their work to find innovative treatment solutions.
Read more: prostatecanceruk.org/research/res...
Since 2013 we have supported their work to find innovative treatment solutions.
Read more: prostatecanceruk.org/research/res...
January 22, 2025 at 8:47 PM
Professor Helen McCarthy and her team @qubelfastofficial.bsky.social are developing an mRNA vaccine to treat #prostatecancer that has spread or come back.
Since 2013 we have supported their work to find innovative treatment solutions.
Read more: prostatecanceruk.org/research/res...
Since 2013 we have supported their work to find innovative treatment solutions.
Read more: prostatecanceruk.org/research/res...
How does #prostatecancer recur after radiotherapy?
Alisha Pati-Alam, Susan Heavey and the team at UCL highlight this key question in their commentary of an important new meta-analysis on salvage therapies.
Grab a ☕and read more: doi.org/10.1038/s413...
Alisha Pati-Alam, Susan Heavey and the team at UCL highlight this key question in their commentary of an important new meta-analysis on salvage therapies.
Grab a ☕and read more: doi.org/10.1038/s413...
January 22, 2025 at 9:08 AM
How does #prostatecancer recur after radiotherapy?
Alisha Pati-Alam, Susan Heavey and the team at UCL highlight this key question in their commentary of an important new meta-analysis on salvage therapies.
Grab a ☕and read more: doi.org/10.1038/s413...
Alisha Pati-Alam, Susan Heavey and the team at UCL highlight this key question in their commentary of an important new meta-analysis on salvage therapies.
Grab a ☕and read more: doi.org/10.1038/s413...
Our @prostatecanceruk.bsky.social Researcher Mentoring Scheme carefully matches mentees with mentors who have the right experience to support you work towards your individual career goals.
Register now to be a mentor, a mentee, or both! 👇
prostatecanceruk.org/research/for...
Register now to be a mentor, a mentee, or both! 👇
prostatecanceruk.org/research/for...
January 20, 2025 at 7:22 PM
Our @prostatecanceruk.bsky.social Researcher Mentoring Scheme carefully matches mentees with mentors who have the right experience to support you work towards your individual career goals.
Register now to be a mentor, a mentee, or both! 👇
prostatecanceruk.org/research/for...
Register now to be a mentor, a mentee, or both! 👇
prostatecanceruk.org/research/for...
[7/8]
The team hope this research leads to clinical trials in prostate cancer and they plan to look for biomarkers that predict which men may have the best response to NXP800, with the long-term goal of a new treatment option for men whose cancer has become resistant to hormone therapy.
The team hope this research leads to clinical trials in prostate cancer and they plan to look for biomarkers that predict which men may have the best response to NXP800, with the long-term goal of a new treatment option for men whose cancer has become resistant to hormone therapy.
January 16, 2025 at 3:52 PM
[7/8]
The team hope this research leads to clinical trials in prostate cancer and they plan to look for biomarkers that predict which men may have the best response to NXP800, with the long-term goal of a new treatment option for men whose cancer has become resistant to hormone therapy.
The team hope this research leads to clinical trials in prostate cancer and they plan to look for biomarkers that predict which men may have the best response to NXP800, with the long-term goal of a new treatment option for men whose cancer has become resistant to hormone therapy.
[6/8]
NXP800 inhibited growth in patient-derived explants, and slowed tumour expansion in mouse xenografts. Without the drug, 100% of xenograft tumours doubled in size by 38 days, but when treated with NXP800, only 37.5% of tumours reached that size within the same time frame.
NXP800 inhibited growth in patient-derived explants, and slowed tumour expansion in mouse xenografts. Without the drug, 100% of xenograft tumours doubled in size by 38 days, but when treated with NXP800, only 37.5% of tumours reached that size within the same time frame.
January 16, 2025 at 3:52 PM
[6/8]
NXP800 inhibited growth in patient-derived explants, and slowed tumour expansion in mouse xenografts. Without the drug, 100% of xenograft tumours doubled in size by 38 days, but when treated with NXP800, only 37.5% of tumours reached that size within the same time frame.
NXP800 inhibited growth in patient-derived explants, and slowed tumour expansion in mouse xenografts. Without the drug, 100% of xenograft tumours doubled in size by 38 days, but when treated with NXP800, only 37.5% of tumours reached that size within the same time frame.
[5/8]
Further elucidating its mechanism of action, NXP800 was shown to activate the unfolded protein response and inhibit key signalling pathways, including AR- and E2F-mediated transcription. The heat shock gene expression signature was significantly associated with Hallmark E2F targets.
Further elucidating its mechanism of action, NXP800 was shown to activate the unfolded protein response and inhibit key signalling pathways, including AR- and E2F-mediated transcription. The heat shock gene expression signature was significantly associated with Hallmark E2F targets.
January 16, 2025 at 3:52 PM
[5/8]
Further elucidating its mechanism of action, NXP800 was shown to activate the unfolded protein response and inhibit key signalling pathways, including AR- and E2F-mediated transcription. The heat shock gene expression signature was significantly associated with Hallmark E2F targets.
Further elucidating its mechanism of action, NXP800 was shown to activate the unfolded protein response and inhibit key signalling pathways, including AR- and E2F-mediated transcription. The heat shock gene expression signature was significantly associated with Hallmark E2F targets.
[4/8]
Intriguingly, NXP800 also inhibited the growth of AR-independent prostate cancer cells, indicating its anti-tumour activity is not solely due to blocking AR signalling.
Intriguingly, NXP800 also inhibited the growth of AR-independent prostate cancer cells, indicating its anti-tumour activity is not solely due to blocking AR signalling.
January 16, 2025 at 3:52 PM
[4/8]
Intriguingly, NXP800 also inhibited the growth of AR-independent prostate cancer cells, indicating its anti-tumour activity is not solely due to blocking AR signalling.
Intriguingly, NXP800 also inhibited the growth of AR-independent prostate cancer cells, indicating its anti-tumour activity is not solely due to blocking AR signalling.
[3/8]
Conversely, the inhibitor drug NXP800 decreased AR signalling, reduced AR and AR-V7 protein expression, DNA binding and transactivation, and inhibited growth of prostate cancer cells that are resistant to the hormone therapy enzalutamide.
Conversely, the inhibitor drug NXP800 decreased AR signalling, reduced AR and AR-V7 protein expression, DNA binding and transactivation, and inhibited growth of prostate cancer cells that are resistant to the hormone therapy enzalutamide.
January 16, 2025 at 3:52 PM
[3/8]
Conversely, the inhibitor drug NXP800 decreased AR signalling, reduced AR and AR-V7 protein expression, DNA binding and transactivation, and inhibited growth of prostate cancer cells that are resistant to the hormone therapy enzalutamide.
Conversely, the inhibitor drug NXP800 decreased AR signalling, reduced AR and AR-V7 protein expression, DNA binding and transactivation, and inhibited growth of prostate cancer cells that are resistant to the hormone therapy enzalutamide.
[2/8]
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social conducted transcriptome analysis on biopsies from men with hormone-therapy resistant cancer, revealing higher levels of heat shock gene expression correlated with more androgen receptor (AR) signalling and worse overall survival.
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social conducted transcriptome analysis on biopsies from men with hormone-therapy resistant cancer, revealing higher levels of heat shock gene expression correlated with more androgen receptor (AR) signalling and worse overall survival.
January 16, 2025 at 3:52 PM
[2/8]
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social conducted transcriptome analysis on biopsies from men with hormone-therapy resistant cancer, revealing higher levels of heat shock gene expression correlated with more androgen receptor (AR) signalling and worse overall survival.
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social conducted transcriptome analysis on biopsies from men with hormone-therapy resistant cancer, revealing higher levels of heat shock gene expression correlated with more androgen receptor (AR) signalling and worse overall survival.
Could targeting the Heat Shock Factor 1 (HSF1) pathway be a new avenue for treating hormone therapy-resistant #prostatecancer?
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social share their exciting new findings.
Grab a ☕and read: doi.org/10.1158/1078...
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social share their exciting new findings.
Grab a ☕and read: doi.org/10.1158/1078...
January 14, 2025 at 4:45 PM
Could targeting the Heat Shock Factor 1 (HSF1) pathway be a new avenue for treating hormone therapy-resistant #prostatecancer?
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social share their exciting new findings.
Grab a ☕and read: doi.org/10.1158/1078...
@asharpmedonc.bsky.social and the team @icrlondon.bsky.social share their exciting new findings.
Grab a ☕and read: doi.org/10.1158/1078...
Join our Researcher Mentoring Scheme and help shape the future of #prostatecancer research!
Whether you're seeking career-focused support and development, or an opportunity to nurture the next generation:
👇Register to be a mentee, a mentor, or both!
prostatecanceruk.org/research/for...
Whether you're seeking career-focused support and development, or an opportunity to nurture the next generation:
👇Register to be a mentee, a mentor, or both!
prostatecanceruk.org/research/for...
January 13, 2025 at 3:19 PM
Join our Researcher Mentoring Scheme and help shape the future of #prostatecancer research!
Whether you're seeking career-focused support and development, or an opportunity to nurture the next generation:
👇Register to be a mentee, a mentor, or both!
prostatecanceruk.org/research/for...
Whether you're seeking career-focused support and development, or an opportunity to nurture the next generation:
👇Register to be a mentee, a mentor, or both!
prostatecanceruk.org/research/for...
🌟New Funding Call Opening Soon 🌟
We urgently need new evidence to update national policy and improve #prostatecancer outcomes for Black men and men experiencing health inequity.
Our Real-World Evidence for Health Equity Awards open on 1 Feb 2025.
🔗Read more:
prostatecanceruk.org/research/for...
We urgently need new evidence to update national policy and improve #prostatecancer outcomes for Black men and men experiencing health inequity.
Our Real-World Evidence for Health Equity Awards open on 1 Feb 2025.
🔗Read more:
prostatecanceruk.org/research/for...
January 9, 2025 at 4:42 PM
🌟New Funding Call Opening Soon 🌟
We urgently need new evidence to update national policy and improve #prostatecancer outcomes for Black men and men experiencing health inequity.
Our Real-World Evidence for Health Equity Awards open on 1 Feb 2025.
🔗Read more:
prostatecanceruk.org/research/for...
We urgently need new evidence to update national policy and improve #prostatecancer outcomes for Black men and men experiencing health inequity.
Our Real-World Evidence for Health Equity Awards open on 1 Feb 2025.
🔗Read more:
prostatecanceruk.org/research/for...
𝗠𝗮𝗸𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 is almost full!🔥
🌟Register now for the 𝗹𝗮𝘀𝘁 𝗳𝗲𝘄 𝗽𝗹𝗮𝗰𝗲𝘀.
🖼️Submit 𝗽𝗼𝘀𝘁𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁𝘀 by 𝟭𝟱 𝗝𝗮𝗻.
🚀Expand your network and build your skills #prostatecancer #ECRs.
👇Find out more and register through the webpage.
prostatecanceruk.org/research/for...
January 9, 2025 at 2:29 PM
𝗠𝗮𝗸𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 is almost full!🔥
🌟Register now for the 𝗹𝗮𝘀𝘁 𝗳𝗲𝘄 𝗽𝗹𝗮𝗰𝗲𝘀.
🖼️Submit 𝗽𝗼𝘀𝘁𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁𝘀 by 𝟭𝟱 𝗝𝗮𝗻.
🚀Expand your network and build your skills #prostatecancer #ECRs.
👇Find out more and register through the webpage.
prostatecanceruk.org/research/for...
Dr Ning Wang and his team @fohsheffield.bsky.social and the Uni of Leicester have shown that load-bearing exercise can reduce the spread of #prostatecancer to the bones.
Since 2017, we have funded their work to help men live longer, healthier lives.
📙Read more: prostatecanceruk.org/research/res...
Since 2017, we have funded their work to help men live longer, healthier lives.
📙Read more: prostatecanceruk.org/research/res...
January 8, 2025 at 7:07 PM
Dr Ning Wang and his team @fohsheffield.bsky.social and the Uni of Leicester have shown that load-bearing exercise can reduce the spread of #prostatecancer to the bones.
Since 2017, we have funded their work to help men live longer, healthier lives.
📙Read more: prostatecanceruk.org/research/res...
Since 2017, we have funded their work to help men live longer, healthier lives.
📙Read more: prostatecanceruk.org/research/res...
@prostatecanceruk.bsky.social are dedicated to supporting Early Career Researchers in #prostatecancer
Register for the final places at Making Progress🔬🧪🧫🥼🧬
💷Attendance is free
📣Travel costs paid for speakers and poster presenters
🚂New travel bursary
Read more prostatecanceruk.org/research/for...
Register for the final places at Making Progress🔬🧪🧫🥼🧬
💷Attendance is free
📣Travel costs paid for speakers and poster presenters
🚂New travel bursary
Read more prostatecanceruk.org/research/for...
December 13, 2024 at 9:58 AM
@prostatecanceruk.bsky.social are dedicated to supporting Early Career Researchers in #prostatecancer
Register for the final places at Making Progress🔬🧪🧫🥼🧬
💷Attendance is free
📣Travel costs paid for speakers and poster presenters
🚂New travel bursary
Read more prostatecanceruk.org/research/for...
Register for the final places at Making Progress🔬🧪🧫🥼🧬
💷Attendance is free
📣Travel costs paid for speakers and poster presenters
🚂New travel bursary
Read more prostatecanceruk.org/research/for...
[7/7] Prostate Cancer UK are proud to have launched the £42m TRANSFORM trial to find the best way to screen for prostate cancer, so one day all men at risk are invited for regular tests to find aggressive prostate cancer in time for a cure.
prostatecanceruk.org/research/for...
prostatecanceruk.org/research/for...
December 10, 2024 at 10:16 AM
[7/7] Prostate Cancer UK are proud to have launched the £42m TRANSFORM trial to find the best way to screen for prostate cancer, so one day all men at risk are invited for regular tests to find aggressive prostate cancer in time for a cure.
prostatecanceruk.org/research/for...
prostatecanceruk.org/research/for...
[6/7] The new diagnostic pathway resulted in a 79% reduction in harm, with the most serious harm (sepsis) decreasing by 90%. These encouraging results suggest the time is now right for large scale screening trials to find the right way to screen men for prostate cancer.
December 10, 2024 at 10:16 AM
[6/7] The new diagnostic pathway resulted in a 79% reduction in harm, with the most serious harm (sepsis) decreasing by 90%. These encouraging results suggest the time is now right for large scale screening trials to find the right way to screen men for prostate cancer.
[3/7] However, the impact of introducing pre biopsy mpMRI and transperineal MRI guided biopsies to the diagnostic pathway has not yet been formally analysed in any screening trial.
December 10, 2024 at 10:16 AM
[3/7] However, the impact of introducing pre biopsy mpMRI and transperineal MRI guided biopsies to the diagnostic pathway has not yet been formally analysed in any screening trial.
[2/7] Prostate cancer screening with the PSA blood test is not currently recommended in the UK because clinical trials in the past showed the harms of screening outweighed the benefits.
December 10, 2024 at 10:16 AM
[2/7] Prostate cancer screening with the PSA blood test is not currently recommended in the UK because clinical trials in the past showed the harms of screening outweighed the benefits.
1/7] Exciting analysis by @prostatecanceruk.bsky.social re-evaluates the harm to benefit ratio in #prostatecancer screening.
Data published by ESMO show that including new technologies in an updated diagnostic pathway results in safer, more effective screening.🧵
doi.org/10.1016/j.es...
Data published by ESMO show that including new technologies in an updated diagnostic pathway results in safer, more effective screening.🧵
doi.org/10.1016/j.es...
December 10, 2024 at 10:16 AM
1/7] Exciting analysis by @prostatecanceruk.bsky.social re-evaluates the harm to benefit ratio in #prostatecancer screening.
Data published by ESMO show that including new technologies in an updated diagnostic pathway results in safer, more effective screening.🧵
doi.org/10.1016/j.es...
Data published by ESMO show that including new technologies in an updated diagnostic pathway results in safer, more effective screening.🧵
doi.org/10.1016/j.es...
[6/7]
Detection of POLQ-mediated microhomology-mediated end joining as a likely mechanism of PARP inhibitor resistance could lead to the development of new treatment options, such as combined PARP/POLQ inhibition, keeping treatments working and helping men live longer, healthier lives.
Detection of POLQ-mediated microhomology-mediated end joining as a likely mechanism of PARP inhibitor resistance could lead to the development of new treatment options, such as combined PARP/POLQ inhibition, keeping treatments working and helping men live longer, healthier lives.
December 9, 2024 at 4:01 PM
[6/7]
Detection of POLQ-mediated microhomology-mediated end joining as a likely mechanism of PARP inhibitor resistance could lead to the development of new treatment options, such as combined PARP/POLQ inhibition, keeping treatments working and helping men live longer, healthier lives.
Detection of POLQ-mediated microhomology-mediated end joining as a likely mechanism of PARP inhibitor resistance could lead to the development of new treatment options, such as combined PARP/POLQ inhibition, keeping treatments working and helping men live longer, healthier lives.